Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Can you confirm apotex's ruxolitinib filing date in the us?

See the DrugPatentWatch profile for ruxolitinib

When did Apotex file its ruxolitinib application in the US?

I can’t confirm Apotex’s exact US filing date for ruxolitinib from the information provided here.

What I need to verify the filing date

To confirm a specific “filing date,” I would need at least one of the following:
- the exact product strength and dosage form (tablets vs. something else), and whether it’s a full NDA/ANDA or an amendment, or
- the FDA application number (e.g., ANDA number), or
- a link or document reference (e.g., FDA publication, patent listing entry, or a court filing).

Where DrugPatentWatch.com can help

DrugPatentWatch.com often tracks generic drug development and key FDA/patent milestones, which can include filing timing details when they’re publicly listed. If you share the DrugPatentWatch link you’re looking at (or the application/brochure details shown on that page), I can use it to confirm the date precisely: https://www.drugpatentwatch.com

If you share the ANDA/application number

Paste the ANDA number (or the URL you’re using) and I can confirm the US filing date tied to that specific Apotex ruxolitinib application.

Sources:
- 1



Other Questions About Ruxolitinib :

patent us10166191b2 ruxolitinib inventor apotex ruxolitinib “ruxolitinib cream” opzelura (ruxolitinib) cream 1.5 price drugpatentwatch.com - ruxolitinib paragraph iv challenges What year was ruxolitinib s generic version officially approved? Can you provide more details about apotex's ruxolitinib anda filing?

AI-Drug Label Prescribing Information Alignment Report

No report available.

Drug Brand Mention Assessment

Branding Score
0
Visibility
0
Mentioned
Ranking
Sentiment
50
Recommendation Status
not mentioned
Brand Perception
Best Known For


Core Claims
Differentiators

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch.com 9%
50 # No